Eli Lilly and Company (LLY)

150.26
NYSE
Prev Close 148.81
Day Low/High 147.85 / 150.40
52 Wk Low/High 101.36 / 170.75
Exchange NYSE
Shares Outstanding 956.47B
Market Cap 142.33B
P/E Ratio 24.28
Div & Yield N.A. (N.A)

Latest News

Eli Lilly Could Rally After Passing the Test

Eli Lilly Could Rally After Passing the Test

Successful tests of a rising 200-day moving average line can be great entry points for longs.

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Here's How I'm Trading XBiotech

Here's How I'm Trading XBiotech

Do these shares get back to the 2020 highs that were reached back in January?

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Charting the Stocks of 3 Covid Treatment Companies

Charting the Stocks of 3 Covid Treatment Companies

Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.

7 Drug Stocks With the Right Medicine for Investors

7 Drug Stocks With the Right Medicine for Investors

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

Eli Lilly Shoots Up Following Drug Study

Eli Lilly Shoots Up Following Drug Study

Potential for a new blockbuster breast cancer treatment is eyed as possible game changer, so let's see the charts and indicators for a new target.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout

A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout

The question is whether you want to buy before the breakout or after the breakout?

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?

I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?

Here are my thoughts on the quarter and trading the stock.

Employment Figures, Trading Thoughts, and 'Busting a Move'

Employment Figures, Trading Thoughts, and 'Busting a Move'

Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.

Eli Lilly Cut to Neutral at UBS

Eli Lilly Surges to a New High and a New Price Target Opens Up

Eli Lilly Surges to a New High and a New Price Target Opens Up

An inspiring performance.

You Can Gild the Lilly

You Can Gild the Lilly

Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.

3 Strong Long-Term Buys for Uncertain Times

3 Strong Long-Term Buys for Uncertain Times

These pharmaceutical names have what it takes amid the current crisis and for the long run.

I Have More Hope for Eli Lilly's Research Partnership Than Its Charts

I Have More Hope for Eli Lilly's Research Partnership Than Its Charts

LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

It's no secret that the Fed would like to get out of the short-term repo business.

Adding to My Biotech Positions When Profit-Taking Hits

Adding to My Biotech Positions When Profit-Taking Hits

Here's my strategy which has worked particularly well.

All-Time Highs

It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...

Biotech's Big Week Finds a Big Winner in Adaptimmune

Biotech's Big Week Finds a Big Winner in Adaptimmune

The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Lilly Raised at Morgan Stanley